Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**CG428** is an investigational topical proprietary botanical lotion developed by Legacy Healthcare for chemotherapy-induced alopecia, including persistent or permanent chemotherapy-induced alopecia in cancer survivors. It contains a four-botanical blend of **Allium cepa** onion, **Citrus limon** citrus, **Theobroma cacao** cocoa, and **Paullinia cupana** guarana. The proposed activity is local modulation of hair-follicle apoptosis and scalp inflammation, with the aim of restoring normal hair cycling and promoting hair regrowth. In a small randomized, double-blind pilot study in breast cancer survivors with permanent chemotherapy-induced alopecia, CG428 was generally tolerated and showed non-significant trends toward improved hair density and patient-reported improvement versus placebo. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/botanical-lotion-cg428))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CG428.